Table 3.
Association with AVF Thrombosis | |||||||||
---|---|---|---|---|---|---|---|---|---|
Year | First Author (References) | Study Type | n | LA | IgG aCL | IgM aCL | IgG aβ2GPI | IgM aβ2GPI | Other |
1991 | F. Garcia-Martin [30] | retrospective | 51 | x | ✓ | ||||
1992 | S. L. Chew [16] | prospective | 60 | x | x | ||||
1995 | P. Brunet [19] | cross-sectional | 97 | ✓ | x | ||||
1995 | R. Prakash [20] | retrospective | 17 | ? | |||||
1999 | J. George [34] | case-control | 81 | x | x | ||||
1999 | B. J. Manns [35] | cross-sectional | 118 | x | |||||
2002 | Y.S. Haviv [31] | retrospective | 54 | ✓ | ✓ | x | x | ||
2002 | I. Palomo [36] | retrospective | 208 | x | x | aPS | |||
2003 | M. R.N. Nampoory [37] | retrospective | 82 | ✓ | x | x | aPS | ||
2003 | Y-C. Chuang [38] | cross-sectional | 48 | ? | ? | ||||
2004 | D. Molino [39] | retrospective | 40 | x | ✓ | ✓ | |||
2005 | F-R. Chuang [27] | cross-sectional | 483 | x | |||||
2005 | G. A. Knoll [40] | case-control | 419 | x | x | x | |||
2005 | F. Gültekin [41] | retrospective | 103 | x | x | ||||
2006 | J. Roozbeh [17] | prospective | 171 | x | |||||
2009 | S. Ozmen [18] | cross-sectional | 103 | x | x | ||||
2012 | A. Serrano [21] | prospective | 124 | x | x | x | x | IgA aβ2GPI | |
2013 | B. Salmela [22] | retrospective | 219 | x | x | x | |||
2013 | S. Hadhri [42] | case-control | 101 | IgA aβ2GPI | |||||
2014 | S. Bataille [28] | retrospective | 192 | ✓ | |||||
2016 | F. I. Fadel [43] | Prospective | 55 | ✓ | |||||
2019 | C. Grupp [44] | prospective | 70 | ✓ | ✓ | ✓ | IgA aCL | ||
2022 | S. R. Anapalli [45] | cross-sectional | 100 | ✓ | ✓ | ||||
2020 | P. R. J. Ames [15] | meta-analysis | 1554 | ✓ | |||||
511 | ✓ |
aCL: anticardiolipin antibody, aPS: antiphosphatidyl serin antibody, AVF: arteriovenous fistula, aβ2GPI: anti-β2 glycoprotein I antibody, LA: lupus anticoagulant.